NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 284 filers reported holding NEKTAR THERAPEUTICS in Q4 2019. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $736 | -15.8% | 230 | 0.0% | 0.00% | – |
| Q2 2022 | $874 | -29.5% | 230 | 0.0% | 0.00% | – |
| Q1 2022 | $1,240 | -80.9% | 230 | -52.1% | 0.00% | – |
| Q4 2021 | $6,485 | -24.8% | 480 | 0.0% | 0.00% | – |
| Q3 2021 | $8,621 | +79.4% | 480 | +71.4% | 0.00% | – |
| Q2 2021 | $4,805 | -28.3% | 280 | -16.4% | 0.00% | – |
| Q1 2021 | $6,700 | +17.6% | 335 | 0.0% | 0.00% | – |
| Q4 2020 | $5,695 | +2.5% | 335 | 0.0% | 0.00% | – |
| Q3 2020 | $5,558 | -67.4% | 335 | -54.4% | 0.00% | -100.0% |
| Q2 2020 | $17,023 | +29.7% | 735 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $13,120 | -17.3% | 735 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $15,865 | +18.5% | 735 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $13,388 | -29.7% | 735 | +37.4% | 0.00% | -50.0% |
| Q2 2019 | $19,035 | +18.0% | 535 | +11.5% | 0.00% | 0.0% |
| Q1 2019 | $16,128 | -6.5% | 480 | -8.6% | 0.00% | 0.0% |
| Q4 2018 | $17,257 | -46.1% | 525 | 0.0% | 0.00% | -50.0% |
| Q3 2018 | $32,004 | +12.0% | 525 | -10.3% | 0.00% | 0.0% |
| Q2 2018 | $28,566 | – | 585 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 432,952 | $1,385,000 | 0.91% |
| GREAT POINT PARTNERS LLC | 447,820 | $1,433,000 | 0.34% |
| Birchview Capital, LP | 128,000 | $410,000 | 0.29% |
| Edgestream Partners, L.P. | 1,047,636 | $3,352,000 | 0.26% |
| Rhenman & Partners Asset Management AB | 550,000 | $2,068,000 | 0.22% |
| CM Management, LLC | 50,000 | $160,000 | 0.18% |
| TANG CAPITAL MANAGEMENT LLC | 430,037 | $1,376,000 | 0.17% |
| PDT Partners, LLC | 307,953 | $985,000 | 0.15% |
| Virtus ETF Advisers LLC | 72,018 | $230,000 | 0.09% |
| ALGERT GLOBAL LLC | 476,412 | $1,525,000 | 0.09% |